Kvistgard
KVISTGRD, Denmark, November 30 - Bavarian Nordic A/S (OMX: BAVA) announced today that the company expects
to file a New Drug Submission (NDS) for its third-generation smallpox
vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010.
KVISTGRD, Denmark, November 17 - Bavarian Nordic A/S (OMX: BAVA) announced today that BARDA (Biomedical
Advanced Research and Development Authority) has awarded a new contract to
Bavarian Nordic for the development of a freeze-dried version of its
IMVAMUNE(R) smallpox vaccine with a total prospective value of USD 40
million.
KVISTGARD, Denmark, November 11 - Today Bavarian Nordic published the company's third quarterly report
2009.
KVISTGARD, Denmark - Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed.
